The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment

Tito R Mendoza, Loretta A Williams, Qiuling Shi, Xin Shelley Wang, Oluwatosin Bamidele, Jeanie F Woodruff, Charles S Cleeland, Tito R Mendoza, Loretta A Williams, Qiuling Shi, Xin Shelley Wang, Oluwatosin Bamidele, Jeanie F Woodruff, Charles S Cleeland

Abstract

Background: The validation of the Treatment-induced Neuropathy Assessment Scale (TNAS v2.0), a patient-reported outcome measure of symptoms associated with cancer treatment-induced peripheral neuropathy (TIPN), was previously reported. Further patient input (qualitative interviewing, cognitive debriefing) suggested that the measure should be modified to better reflect the TIPN experience. We report the performance of a revised version (TNAS v3.0) for assessing TIPN across cancer treatments. This TNAS version incorporates extensive patient input, in accordance with FDA guidance on the development of patient-reported outcomes measures. Patients with multiple myeloma, colorectal cancer, or gynecological cancer treated with bortezomib, oxaliplatin, or taxane-platinum combination therapy, respectively, completed the TNAS v3.0, European Organization for Research and Treatment of Cancer Chemotherapy-Induced Peripheral Neuropathy (EORTC-CIPN20), and a cognitive debriefing survey during a scheduled clinic visit. Patients also participated in in-depth qualitative interviews about their TIPN symptoms. The psychometric properties of the TNAS v3.0 were evaluated.

Results: Cognitive debriefing survey results were summarized and showed that most patients found the items easy to complete, comprehensible, acceptable, and not redundant. A notable change from TNAS v2.0 was the separation of "numbness" from "tingling," although these 2 items remained the most severe, followed by a new "pain" item. The Cronbach coefficient alphas for the 9-item TNAS were 0.88 and 0.90 at the first and second administrations, respectively, indicating good reliability. The test-retest reliability of the TNAS was 0.97. The correlation coefficients for the 9-item TNAS and the EORTC-CIPN20 were 0.69 for the sensory subscale, 0.70 for the motor subscale, and 0.32 for the autonomic subscale, indicating good validity.

Conclusion: This psychometric evaluation showed that the TNAS v3.0 is valid and reliable. Further research is needed to determine clinically meaningful differences in TNAS v3.0 scores and demonstrate its responsiveness over time.

Keywords: CIPN; Chemotherapy-induced peripheral neuropathy; Colorectal cancer; Gynecological cancer; Multiple myeloma; Patient-reported outcomes; Peripheral neuropathy; Validation.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL. American Society of Clinical O: Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:1941–1967. doi: 10.1200/JCO.2013.54.0914.
    1. Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin. 2013;63:419–437. doi: 10.3322/caac.21204.
    1. Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature. Cancer Manag Res. 2014;6:135–147. doi: 10.2147/CMAR.S44261.
    1. Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): What we need and what we know. J Peripher Nerv Syst. 2014;19:66–76. doi: 10.1111/jns5.12073.
    1. Esin E, Yalcin S. Neuropathic cancer pain: What we are dealing with? How to manage it? Onco Targets Ther. 2014;7:599–618.
    1. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. J Clin Oncol. 2013;31:2699–2707. doi: 10.1200/JCO.2013.49.1514.
    1. Gewandter JS, Burke L, Cavaletti G, Dworkin RH, Gibbons C, Gover TD, Herrmann DN, McArthur JC, McDermott MP, Rappaport BA, Reeve BB, Russell JW, Smith AG, Smith SM, Turk DC, Vinik AI, Freeman R. Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. Muscle Nerve. 2017;55:366–372. doi: 10.1002/mus.25264.
    1. Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS. Measuring therapy-induced peripheral neuropathy: Preliminary development and validation of the treatment-induced neuropathy assessment scale. J Pain. 2015;16:1032–1043. doi: 10.1016/j.jpain.2015.07.002.
    1. Cleeland CS, Mendoza TR. Symptom measurement by patient report. In: Cleeland CS, Fisch MJ, Dunn AJ, editors. Cancer symptom science: Measurement, mechanisms, and management. Cambridge: Cambridge University Press; 2011. pp. 268–284.
    1. US Department of Health and Human Services Food and Drug Administration: Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Available at: . Accessed 19 Mar 2018.
    1. Williams, L. A., Garcia-Gonzalez, A., Mendoza, T. R., Haq, S., & Cleeland, C. S. (2018). Concept domain validation and item generation for the treatment-induced neuropathy assessment scale (TNAS). Support Care Cancer [Epub ahead of print].
    1. Dawes RM. The robust beauty of improper linear models in decision making. Am Psychol. 1979;34:571–582. doi: 10.1037/0003-066X.34.7.571.
    1. Cox DR, Fitzpatrick R, Fletcher AE, Gore SM, Spiegelhalter DJ, Jones DR. Quality-of-life assessment: Can we keep it simple? J Roy Stat Soc a Sta. 1992;155:353–393. doi: 10.2307/2982889.
    1. Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: The reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 questionnaire. Qual Life Res. 2013;22:2787–2799. doi: 10.1007/s11136-013-0379-8.
    1. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lanteri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R, Group EQoL The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer. 2005;41:1135–1139. doi: 10.1016/j.ejca.2005.02.012.
    1. Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ, Lachance DH. Natural history of paclitaxel-associated acute pain syndrome: Prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29:1472–1478. doi: 10.1200/JCO.2010.33.0308.
    1. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, Aaronson NK, Satele DV, Mattar BI, Green NB, Loprinzi CL. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer. 2012;20:625–632. doi: 10.1007/s00520-011-1141-9.
    1. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 2--assessing respondent understanding. Value Health. 2011;14:978–988. doi: 10.1016/j.jval.2011.06.013.
    1. Willis GB. Cognitive interviewing: A tool for improving questionnaire design. Thousand Oaks: SAGE Publications, Inc.; 2005.
    1. Leidy NK, Vernon M. Perspectives on patient-reported outcomes : Content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics. 2008;26:363–370. doi: 10.2165/00019053-200826050-00002.
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2. Hillsdale: L. Erlbaum Associates; 1988.
    1. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC. Assessing symptom distress in cancer patients: The M.D. Anderson symptom inventory. Cancer. 2000;89:1634–1646. doi: 10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>;2-V.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit